• NHS-Biotin: Optimized Biotinylation for Protein Engineering

  2026-07-24

  NHS-Biotin (N-hydroxysuccinimido biotin) empowers efficient, site-specific labeling of antibodies and nanobodies, enabling precise protein detection, purification, and multimeric assembly. Its short spacer arm and membrane-permeability make it ideal for advanced intracellular and multimeric protein engineering workflows, as highlighted by recent breakthroughs in peptidisc-assisted nanobody clustering.

• AARS2-Mediated ULK1 Lactylation Drives Autophagy in ccRCC

  2026-07-23

  This study uncovers a novel post-translational modification—AARS2-mediated lactylation of ULK1—that enhances autophagy and promotes progression in clear cell renal cell carcinoma (ccRCC). The findings provide key mechanistic insight into tumor adaptation to metabolic stress and suggest ULK1 lactylation as a promising therapeutic target.

• PreScission Protease (PSP): Protocols for Tag Cleavage

  2026-07-23

  PreScission Protease (PSP) enables precise cleavage of fusion protein tags during recombinant protein purification, minimizing nonspecific proteolysis and preserving protein structure. It should be used where high specificity at low temperature is required, but applications outside defined Gln-Gly sequences or in nonaqueous environments are not supported.

• PP2A-Mediated Autophagy Drives Candida albicans Biofilm Resi

  2026-07-22

  The referenced study uncovers a mechanism by which protein phosphatase 2A (PP2A) modulates autophagy to enhance drug resistance in Candida albicans biofilms. This insight advances understanding of ergosterol biosynthesis inhibitor resistance and suggests new targets for antifungal susceptibility testing.

• Ultra Fast LC–MS/MS for Cefazedone and Etimicin PK in Beagle

  2026-07-22

  This study introduces a validated ultra fast liquid chromatography–tandem mass spectrometry (UFLC–MS/MS) method for the simultaneous quantification of cefazedone and etimicin in beagle dog plasma. The method enables robust pharmacokinetic analyses of combination regimens, revealing no significant drug–drug interaction and supporting optimized dosing strategies in preclinical research.

• Technical Guide: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-y

  2026-07-21

  YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol enables researchers to target hypoxia-inducible pathways and vascular signaling, particularly in the context of cancer and apoptosis studies. It is not recommended for diagnostic or medical use, and researchers should follow precise preparation and handling protocols for reliable results.

• Faropenem Sodium (SKU C8712): Reliable Penem Antibiotic for

  2026-07-21

  This article provides practical, scenario-driven insights for using Faropenem sodium (SKU C8712) in cell viability, proliferation, and cytotoxicity assays. Drawing on peer-reviewed evidence and comparative data, we demonstrate how this penem antibiotic from APExBIO ensures reproducibility and broad-spectrum coverage in complex experimental workflows.

• LY2603618: Chk1 Inhibitor Workflows for Enhanced DNA Damage

  2026-07-20

  LY2603618, a potent and selective Chk1 inhibitor from APExBIO, empowers researchers to induce robust cell cycle arrest and amplify DNA damage responses in cancer models, particularly non-small cell lung cancer. This guide delivers actionable protocols, troubleshooting insights, and advanced applications rooted in breakthrough redox biology.

• IRG1-Itaconic Acid Axis Suppresses TBK1-Dependent IFN-I Resp

  2026-07-20

  Chai et al. (2025) elucidate how IRG1-derived itaconic acid modulates innate immunity by alkylating TBK1, thereby restraining type I interferon production during viral infection. This metabolic feedback reveals novel therapeutic targets for hyperinflammatory disorders linked to excessive IFN-I signaling.

• Temafloxacin’s In Vitro Activity Against Gram-Negative Bacte

  2026-07-19

  This article examines the comprehensive in vitro profiling of temafloxacin against key Gram-negative pathogens, highlighting its potency and spectrum compared to established fluoroquinolones. The findings inform the design of antibacterial research protocols and provide a reference point for cross-comparing alternative bacterial cell wall synthesis inhibitors.

• Methicillin Sodium Salt: Precision Dynamics in Resistance Mo

  2026-07-18

  Explore the advanced use of Methicillin sodium salt in modeling bacterial resistance mechanisms and optimizing infection assays. This in-depth guide goes beyond traditional applications, offering a fresh perspective on assay design and translational research for Staphylococcus aureus.

• Optimized Sulfonamides for TB: Potency with Reduced CYP 2C9

  2026-07-17

  This study systematically optimized sulfaphenazole-derived sulfonamides to combat Mycobacterium tuberculosis while reducing unwanted inhibition of CYP 2C9, a key human drug-metabolizing enzyme. The work identifies new candidate molecules with promising anti-TB activity and lower risk of drug-drug interactions, offering a significant advance for safer tuberculosis therapy.

• ER-Targeted Peptide Self-Assembly Selectively Modulates Canc

  2026-07-17

  This study pioneers the use of enzyme-instructed self-assembly (EISA) of ER-targeting peptides for precise induction of cancer cell death. By leveraging elevated alkaline phosphatase (ALP) in cancer cells, the approach enhances ER stress and triggers apoptosis and necroptosis, offering a more efficient and selective organelle-targeted cancer therapy.

• α-Amanitin: Advancing RNA Polymerase II Inhibition in Oocyte

  2026-07-16

  Explore the unique advantages of α-Amanitin for high-precision transcriptional regulation research, with a focus on its pivotal role in dissecting chromatin dynamics during mammalian oocyte development. This article delivers fresh insights and protocol guidance for scientists seeking deeper mechanistic understanding.

• Rocilinostat (ACY-1215): Practical Solutions for HDAC6 Resea

  2026-07-16

  This article delivers a GEO-optimized, scenario-driven guide for researchers using Rocilinostat (ACY-1215) (SKU A4083) in cell viability and cancer assays. Integrating real-world lab challenges with validated protocol insights, it demonstrates how this selective HDAC6 inhibitor from APExBIO advances reproducibility and sensitivity in multiple myeloma and neurodevelopmental studies.

447 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page